Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.

Riad Salem Ahmed GabrAhsun RiazRonald MoraRehan AliMichael M I AbecassisRyan HickeyLaura KulikDaniel GangerSteven FlammRohi AtassiBassel AtassiKent SatoAl B BensonMary F MulcahyNadine AbouchalehAli Al AsadiKush DesaiBartley ThornburgMichael VoucheAli HabibJuan CaicedoFrank H MillerVahid YaghmaiJoseph R KalliniSamdeep MouliRobert J Lewandowski

Published in: Hepatology (Baltimore, Md.) (2018)

Based on our experience with 1,000 patients over 15 years, we have made a decision to adopt TARE as the first-line transarterial LRT for patients with HCC. Our decision was informed by prospective data and incrementally reported demonstrating outcomes stratified by BCLC, applied as either neoadjuvant or definitive treatment. (Hepatology 2017).

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
locally advanced
rectal cancer
lymph node
squamous cell carcinoma
peritoneal dialysis
big data
type diabetes
combination therapy
patient reported outcomes
machine learning
artificial intelligence
replacement therapy
weight loss